Imedex® is an industry leader in providing certified, independent continuing medical education to health care professionals.

November 17-18, 2017

New York, New York

Scientific Agenda

Friday, November 17, 2017

8:00 am

Welcome and introduction
Corey J. Langer, MD, FACP

Session I: Introductory Lectures for the New Millennium

8:05 am

Pre-session audience survey

8:10 am

Emerging role of liquid biopsy
Erica L. Carpenter, MBA, PhD

8:30 am

Lung cancer screening: Challenges and benefits
Jim L. Mulshine, MD

8:50 am

Smoking cessation and controversies surrounding e-cigarettes
Laura Jean Bierut, MD

9:10 am

Panel Q & A

9:25 am

Post-session audience survey

Session II: Early stage NSCLC

9:30 am

Pre-session audience survey

9:35 am

Going beyond positron emission tomography (PET): New imaging approaches
Daniel A. Pryma, MD

9:55 am

Adjuvant therapy: Current practice and emerging strategies
Tracey L. Evans, MD

10:15 am

Panel Q & A

10:35 am

Post-session audience survey

10:40 am

Break

Session III: Locally Advanced NSCLC: The Marriage of Medical, Radiation, and Surgical Oncology

11:00 am

Pre-session audience survey

11:05 am

Locally advanced NSCLC: Combination therapy with targeted and immunotherapy agents
Corey J. Langer, MD, FACP

11:25 am

New radiation approaches for locally advanced NSCLC
Jeffrey D. Bradley, MD

11:45 am

Surgical dilemmas in the management of locally advanced NSCLC
Jessica S. Donington, MD

12:05 pm

Panel Q & A

12:20 pm

Post-session audience survey

12:30 pm

Lunch

Session IV: Special Topics in Lung Cancer

2:00 pm

Pre-session audience survey

2:05 pm

Mesothelioma: Old habits, new directions
Anne S. Tsao, MD

2:25 pm

Squamous cell carcinoma: Is there hope?
Paul K. Paik, MD

2:45 pm

Thymic tumors and other thoracic zebras
Tracey L. Evans, MD

3:05 pm

Break

3:25 pm

Managing inevitable delays in tissue testing results: When to wait; when to intervene
Anne S. Tsao, MD

3:45 pm

Understanding the complexities of the new staging system
Jessica S. Donington, MD

4:05 pm

Panel Q & A

4:20 pm

Post-session audience survey

4:25 pm

Adjourn


Saturday, November 18, 2017

8:00 am

Welcome and introduction
Corey J. Langer, MD, FACP

Session V: Advanced NSCLC

8:10 am

Pre-session audience survey

8:15 am

Front-line targeted therapy for advanced EGFR-positive disease
Tracey L. Evans, MD

8:35 am

Managing EGFR-resistant disease: T790 and beyond
Lyudmila Bazhenova, MD

8:55 am

Role of monoclonal antibodies: Can EGFR mABs be resuscitated?
Roy S. Herbst, MD, PhD

9:15 am

Panel Q & A

9:30 am

Post-session audience survey

9:40 am

Break

Session VI: Supportive Therapy

10:10 am

Pre-session audience survey

10:15 am

Patient education and management of treatment expectation
Beth Eaby-Sandy, MSN, CRNP

10:35 am

Complementary and alternative therapy
Jun J. Mao, MD, MSCE

10:55 am

Shared decision making at the end of life
Jennifer S. Temel, MD

11:15 am

Panel Q & A

11:35 am

Post-session audience survey

11:45 am

Lunch

Session VII: Biomarkers and Targeted Therapy

1:15 pm

Pre-session audience survey

1:20 pm

EML4/ALK and ROS-1: How do we sequence therapies
Alice T. Shaw, MD, PhD

1:40 pm

Potential and progress in targeting less common markers: HER2, BRAF, KRAS, MET, TRK, and RET
Joshua Bauml, MD

2:00 pm

SCLC: Are we witnessing any progress
Charles Rudin, MD, PhD

2:20 pm

Panel Q & A

2:35 pm

Post-session audience survey

2:40 pm

Break

Session VIII: Immunotherapy and Lung Cancer

3:00 pm

Pre-session audience survey

3:05 pm

Immunotherapy in lung cancer: Panacea vs. reality?
Joshua Bauml, MD

3:25 pm

Transitioning checkpoint blockade from the second to first line in advanced NSCLC
Vassiliki A. Papadimitrakopoulou, MD

3:45 pm

Monitoring, managing, and mitigating immune-related adverse events
Lyudmila Bazhenova, MD

4:05 pm

Immunotherapy: Moving beyond PD1 and PDL1 inhibitors
Vassiliki A. Papadimitrakopoulou, MD

4:25 pm

Panel Q & A

4:40 pm

Post-session ARS survey

4:45 pm

Adjourn